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Multiple sclerosis relapse phenotype is an important, neglected determinant of disease-outcome: Commentary
Michael Hutchinson
Thomas Scott, who stimulated this debate, asks: 'Why has the study of relapse phenotype been so delayed?'. 1 Both protagonists agree that relapses in multiple sclerosis (MS) do matter (the subject of a previous debate), so let us get that out of the way. 2 Also there are numerous studies, most notably from the Lyon database, indicating that the phenotype of the onset episode has predictive value in relation to time to progression. 3 Thirdly, both protagonists agree that the frequency of relapses in the first few years (sometimes measured as the time to the first relapse) is important in relation to time to secondary progression and even time to death. 4 Thus, clearly, we all agree that the relapse phenotype is important early in the disease course.
Thomas Scott argues that we are neglecting relapse phenotype later in the disease. He points to evidence that a motor system relapse with poor recovery in the setting of relapsing MS may herald the onset of secondary progression. 5 A similar finding has been noted in another recent study showing that relapses, usually occurring within five years after the onset of the progressive phase, tended to speed up the time to Expanded Disability Status Scale (EDSS) 6.0. 6 The same authors therefore suggest that it would be reasonable to consider continuing immunomodulatory therapy for up to five years after the onset of the progressive phase.
Of course relapses represent only a very small proportion of total disease activity in patients with MS.
Other controversies have discussed this 'iceberg' effect. It is unsurprising that relapses in the corticospinal pathways tend to speed up the time to reach disability milestones measured by a measure of ambulation, the EDSS. We use this measure in daily practice; this should not mean that sensory relapses and new asymptomatic deep white matter plaques on MRI scanning are irrelevant to the total disease burden in MS and longer-term outcomes.
I would argue that by concentrating on relapse phenotype we ignore our real problem, which is the absence of measures of the ongoing inflammatory burden and the accrual of widespread hidden neuronal and axonal injury. At present we have only the patient report, clinical examination and annual MRI scan to guide therapeutic decisions. Even the clinical examination is imperfect; few neurologists have the time or the resources to perform an adequate cognitive assessment in the clinic. Of course there are academic multidisciplinary clinical centres where neuropsychologists assess patients. The vast majority of patients with relapsing MS in the real world do not have access to adequate cognitive assessment, and thus hidden disease activity is missed.
I well remember a number of patients with optic neuritis as the onset symptom. They had a mild course with infrequent relapses. I reassured them, at 15 years after the onset of the disease, that they had a benign form of multiple sclerosis. 25 years after the onset of the disease, they all became significantly disabled and have subsequently died from complications of their disease. For almost half of the disease course I had reassured them that they had benign disease. Most of them, after 20 years disease course, had significant cognitive impairment, and as has been demonstrated by Maria Pia Amato and colleagues, this is an extremely poor prognostic feature. 7 Grey matter disease is the main enemy, which we, even at this time, cannot measure adequately in every day clinical practice.
Therefore I would tend to disagree with Thomas Scott; I would consider that relapse phenotype is not an important, neglected determinant of disease outcome. What is neglected, even by most conscientious neurologists, is the grey matter disease burden not seen by the MRI scan and not measured in the clinic by neurocognitive assessments, even annually. The work of a number of prominent neuropsychologists has led to the development of validated measures, such as BICAMS among others. 8 We need to bring those measures to the clinic and use them.
Finally we really should get rid of our tendency to characterize relapses as being mild/severe/clinically significant/disabling, and stop basing our treatment decisions on such vague and entirely misleading epithets. As has been debated before, a relapse is a relapse is a relapse. 9 Most of the substrate of eventual neurological disability, which MS patients accrue, is hidden and not measured until it is irreversible.
